What is a stock summary page? Click here for an overview.
Business Description
Arrowhead Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US04280A1007
Description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.05 | |||||
| Equity-to-Asset | 0.05 | |||||
| Debt-to-Equity | 9.99 | |||||
| Debt-to-EBITDA | -0.91 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.68 | |||||
| Beneish M-Score | -17.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -71.8 | |||||
| 3-Year EBITDA Growth Rate | -54.2 | |||||
| 3-Year EPS without NRI Growth Rate | -54.3 | |||||
| 3-Year Book Growth Rate | -27.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 7.29 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 310.76 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.86 | |||||
| 9-Day RSI | 26.8 | |||||
| 14-Day RSI | 29.97 | |||||
| 3-1 Month Momentum % | -5.07 | |||||
| 6-1 Month Momentum % | 6.23 | |||||
| 12-1 Month Momentum % | -30.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.09 | |||||
| Quick Ratio | 6.09 | |||||
| Cash Ratio | 5.9 | |||||
| Days Sales Outstanding | 365 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6 | |||||
| Shareholder Yield % | -11.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -25037.88 | |||||
| Net Margin % | -25588.56 | |||||
| FCF Margin % | -22167.76 | |||||
| ROE % | -263.74 | |||||
| ROA % | -69.25 | |||||
| ROIC % | -145.4 | |||||
| 3-Year ROIIC % | -3668.37 | |||||
| ROC (Joel Greenblatt) % | -145.29 | |||||
| ROCE % | -71.52 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 691 | |||||
| PB Ratio | 32.98 | |||||
| Price-to-Tangible-Book | 39.56 | |||||
| EV-to-EBIT | -2.86 | |||||
| EV-to-Forward-EBIT | -3.18 | |||||
| EV-to-EBITDA | -2.96 | |||||
| EV-to-Forward-EBITDA | -11.42 | |||||
| EV-to-Revenue | 687.53 | |||||
| EV-to-Forward-Revenue | 16.76 | |||||
| EV-to-FCF | -3.28 | |||||
| Price-to-GF-Value | 1.87 | |||||
| Price-to-Median-PS-Value | 18.9 | |||||
| Earnings Yield (Greenblatt) % | -34.93 | |||||
| FCF Yield % | -32.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arrowhead Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.388 | ||
| EPS (TTM) (€) | -4.781 | ||
| Beta | 0.62 | ||
| 3-Year Sharpe Ratio | -0.21 | ||
| 3-Year Sortino Ratio | -0.32 | ||
| Volatility % | 63.67 | ||
| 14-Day RSI | 29.97 | ||
| 14-Day ATR (€) | 0.550187 | ||
| 20-Day SMA (€) | 14.49425 | ||
| 12-1 Month Momentum % | -30.44 | ||
| 52-Week Range (€) | 12.66 - 27.28 | ||
| Shares Outstanding (Mil) | 137.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arrowhead Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arrowhead Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arrowhead Pharmaceuticals Inc Frequently Asked Questions
What is Arrowhead Pharmaceuticals Inc(STU:HDP1)'s stock price today?
The current price of STU:HDP1 is €12.66. The 52 week high of STU:HDP1 is €27.28 and 52 week low is €12.66.
When is next earnings date of Arrowhead Pharmaceuticals Inc(STU:HDP1)?
The next earnings date of Arrowhead Pharmaceuticals Inc(STU:HDP1) is 2025-05-09 Est..
Does Arrowhead Pharmaceuticals Inc(STU:HDP1) pay dividends? If so, how much?
Arrowhead Pharmaceuticals Inc(STU:HDP1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers